Published in Lung Cancer on September 11, 2001
Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med (1999) 11.44
Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol (2001) 6.83
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol (2000) 6.06
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med (1999) 5.84
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol (2001) 4.73
A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med (2000) 4.54
Negative transport & resistance to water flow through plants. Plant Physiol (1961) 4.10
Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles. Cancer (2000) 4.05
Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res (1977) 4.02
Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol (2001) 3.06
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol (1991) 3.01
Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120. J Virol (1989) 3.00
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol (1995) 2.89
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol (2001) 2.73
Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst (1995) 2.64
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol (2007) 2.43
Effect of delay in radiation in the combined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys (1993) 2.42
Reduced subjective awareness of bronchoconstriction provoked by methacholine in elderly asthmatic and normal subjects as measured on a simple awareness scale. Thorax (1992) 2.11
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res (1994) 2.10
An association between the common hereditary hemochromatosis mutation and the factor V Leiden allele in a population with thrombosis. Blood (1998) 2.03
De novo expansion of a (CAG)n repeat in sporadic Huntington's disease. Nat Genet (1993) 2.02
Immunogenicity and safety of PRP-T conjugate vaccine given according to the British accelerated immunisation schedule. Arch Dis Child (1992) 2.02
Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. Int J Radiat Oncol Biol Phys (1994) 2.00
Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol (1995) 1.96
CONCENTRATION-TIME COURSE IN THE PLASMA OF MAN OF RADIOMERCURY INTRODUCED AS A MERCURIAL DIURETIC. J Clin Invest (1949) 1.92
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol (1998) 1.91
Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer (1999) 1.82
Fraction size and dose parameters related to the incidence of pericardial effusions. Int J Radiat Oncol Biol Phys (1998) 1.76
Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis (2013) 1.67
Comparative mapping between Medicago sativa and Pisum sativum. Mol Genet Genomics (2004) 1.63
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol (1999) 1.63
Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol (1998) 1.61
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood (1995) 1.59
Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol (1990) 1.57
Impaired bronchodilator response to albuterol in healthy elderly men and women. Chest (1995) 1.56
Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst (2001) 1.55
Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med (1993) 1.55
Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut (2005) 1.49
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol (1994) 1.49
Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann Neurol (2001) 1.44
Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study. Ann Intern Med (1978) 1.44
Direct detection of a common inversion mutation in the genetic diagnosis of severe hemophilia A. Blood (1994) 1.43
Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol (2012) 1.42
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer (2001) 1.41
Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med (1996) 1.41
Abdominal computed tomography, colonography and radiation exposure: what the surgeon needs to know. Colorectal Dis (2014) 1.40
Counterpoint: better radiation treatment of non-small cell lung cancer using new techniques without elective nodal irradiation. Semin Radiat Oncol (2000) 1.39
Intra-arterial thrombolysis (reteplase) and ReoPro for subacute thrombosis of the distal aorta accomplished by radial arterial access: the radial-kissing-thrombolytic technique. Catheter Cardiovasc Interv (2001) 1.39
Effect of visualization display colour on polyp conspicuity at virtual colonoscopy. Clin Radiol (2008) 1.39
Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: a Phase II study of the Southwest Oncology Group. Cancer (1997) 1.38
Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol (2001) 1.37
18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol (2001) 1.35
Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials (2000) 1.33
Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. Cancer (1999) 1.33
Nephrotic syndrome and acute hepatitis in secondary syphilis. Mil Med (1969) 1.32
E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res (2000) 1.31
A past mutation at isoleucine 397 is now a common cause of moderate/mild haemophilia B. Br J Haematol (1990) 1.29
Epidermal growth factor stimulation of human breast cancer cells in culture. Cancer Res (1980) 1.29
Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg (2001) 1.25
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol (2008) 1.24
Specialized paranodal and interparanodal glial-axonal junctions in the peripheral and central nervous system: a freeze-etching study. Brain Res (1973) 1.23
Lipoid proteinosis in an inbred Namaqualand community. Lancet (1969) 1.22
Dose response effectiveness of propranolol for the treatment of angina pectoris. Circulation (1975) 1.22
Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol (1988) 1.20
Effect of temperature on water transport through plants. Plant Physiol (1961) 1.19
A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg (1993) 1.19
Incidental findings found in "healthy" volunteers during imaging performed for research: current legal and ethical implications. Br J Radiol (2010) 1.18
Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett (2007) 1.17
Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg (2000) 1.15
Primary renal artery stenting: characteristics and outcomes after 363 procedures. Am Heart J (2001) 1.14
The management of ovarian-cancer-caused bowel obstruction. Gynecol Oncol (1981) 1.14
Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol (1993) 1.12
Synchronous multicentric osteosarcoma: the case for metastases. Skeletal Radiol (1997) 1.11
PGG-glucan, a soluble beta-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-kappa B-like factor in human PMN: evidence for a glycosphingolipid beta-(1,3)-glucan receptor. Immunopharmacology (1999) 1.10
The relationship of cognitive, personality, and academic measures to anesthesiology resident clinical performance. Anesth Analg (1999) 1.10
CT enterography: review of technique and practical tips. Br J Radiol (2012) 1.10
A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol (1991) 1.10
Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope (1988) 1.09
Contamination of mononuclear cell suspensions obtained from cancer patients by the Böyum method. Br J Cancer (1978) 1.08
Arthritis in psoriasis. Ann Rheum Dis (1981) 1.08
Management of incidental findings during imaging research in "healthy" volunteers: current UK practice. Br J Radiol (2011) 1.07
Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst (1991) 1.06
Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol (2011) 1.06
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol (2012) 1.05
Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Causes Control (2001) 1.04
The Grainyhead transcription factor Grhl3/Get1 suppresses miR-21 expression and tumorigenesis in skin: modulation of the miR-21 target MSH2 by RNA-binding protein DND1. Oncogene (2012) 1.03
Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group. J Clin Oncol (1993) 1.03
The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin Invest (1997) 1.03